Cargando…

MicroRNA-33b Suppresses Epithelial–Mesenchymal Transition Repressing the MYC–EZH2 Pathway in HER2+ Breast Carcinoma

Downregulation of miR-33b has been documented in many types of cancers and is being involved in proliferation, migration, and epithelial–mesenchymal transition (EMT). Furthermore, the enhancer of zeste homolog 2-gene (EZH2) is a master regulator of controlling the stem cell differentiation and the c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pattanayak, Birlipta, Garrido-Cano, Iris, Adam-Artigues, Anna, Tormo, Eduardo, Pineda, Begoña, Cabello, Paula, Alonso, Elisa, Bermejo, Begoña, Hernando, Cristina, Martínez, María Teresa, Rovira, Ana, Albanell, Joan, Rojo, Federico, Burgués, Octavio, Cejalvo, Juan Miguel, Lluch, Ana, Eroles, Pilar
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2020
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7511588/ https://www.ncbi.nlm.nih.gov/pubmed/33014831 http://dx.doi.org/10.3389/fonc.2020.01661

Ejemplares similares

Role of SALL4 in HER2+ Breast Cancer Progression: Regulating PI3K/AKT Pathway
por: Pattanayak, Birlipta, et al.
Publicado: (2022)

miR-146a-5p Promotes Angiogenesis and Confers Trastuzumab Resistance in HER2+ Breast Cancer
por: Cabello, Paula, et al.
Publicado: (2023)

The miRNA-449 family mediates doxorubicin resistance in triple-negative breast cancer by regulating cell cycle factors
por: Tormo, Eduardo, et al.
Publicado: (2019)

The role of miR-26a and miR-30b in HER2+ breast cancer trastuzumab resistance and regulation of the CCNE2 gene
por: Tormo, Eduardo, et al.
Publicado: (2017)

High VEGFR3 Expression Reduces Doxorubicin Efficacy in Triple-Negative Breast Cancer
por: Torres-Ruiz, Sandra, et al.
Publicado: (2023)

HDAC5 Inhibitors as a Potential Treatment in Breast Cancer Affecting Very Young Women
por: Oltra, Sara S., et al.
Publicado: (2020)

Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer
por: Adam-Artigues, Anna, et al.
Publicado: (2022)

The Antitumor Effect of Metformin Is Mediated by miR-26a in Breast Cancer
por: Cabello, Paula, et al.
Publicado: (2016)

MicroRNAs as a clue to overcome breast cancer treatment resistance
por: Garrido-Cano, Iris, et al.
Publicado: (2021)

Identification of a Two-MicroRNA Signature in Plasma as a Novel Biomarker for Very Early Diagnosis of Breast Cancer
por: Adam-Artigues, Anna, et al.
Publicado: (2021)

Oral Selective Estrogen Receptor Degraders (SERDs) as a Novel Breast Cancer Therapy: Present and Future from a Clinical Perspective
por: Hernando, Cristina, et al.
Publicado: (2021)

Delivery of miR-200c-3p Using Tumor-Targeted Mesoporous Silica Nanoparticles for Breast Cancer Therapy
por: Garrido-Cano, Iris, et al.
Publicado: (2023)

Circulating miR-99a-5p Expression in Plasma: A Potential Biomarker for Early Diagnosis of Breast Cancer
por: Garrido-Cano, Iris, et al.
Publicado: (2020)

Clinical Impact of New Treatment Strategies for HER2-Positive Metastatic Breast Cancer Patients with Resistance to Classical Anti-HER Therapies
por: Tapia, Marta, et al.
Publicado: (2023)

miR‐99a‐5p modulates doxorubicin resistance via the COX‐2/ABCG2 axis in triple‐negative breast cancer: from the discovery to in vivo studies
por: Garrido‐Cano, Iris, et al.
Publicado: (2022)

A two-gene epigenetic signature for the prediction of response to neoadjuvant chemotherapy in triple-negative breast cancer patients
por: Pineda, Begoña, et al.
Publicado: (2019)

Breast Cancer in Very Young Patients in a Spanish Cohort: Age as an Independent Bad Prognostic Indicator
por: Martínez, María Teresa, et al.
Publicado: (2019)

Circulating miR-30b-5p levels in plasma as a novel potential biomarker for early detection of breast cancer
por: Adam-Artigues, A., et al.
Publicado: (2021)

Identification of Candidate Polymorphisms on Stress Oxidative and DNA Damage Repair Genes Related with Clinical Outcome in Breast Cancer Patients
por: Rodrigues, Patricia, et al.
Publicado: (2012)

Associations between Aromatase CYP19 rs10046 Polymorphism and Breast Cancer Risk: From a Case-Control to a Meta-Analysis of 20,098 Subjects
por: Pineda, Begoña, et al.
Publicado: (2013)

Immunological Landscape of HER-2 Positive Breast Cancer
por: Moragon, Santiago, et al.
Publicado: (2022)

Non-canonical NF-κB pathway activation predicts outcome in borderline oestrogen receptor positive breast carcinoma
por: Rojo, Federico, et al.
Publicado: (2016)

miRNA Expression Analysis: Cell Lines HCC1500 and HCC1937 as Models for Breast Cancer in Young Women and the miR-23a as a Poor Prognostic Biomarker
por: Oltra, Sara S, et al.
Publicado: (2020)

PP2A inhibition determines poor outcome and doxorubicin resistance in early breast cancer and its activation shows promising therapeutic effects
por: Rincón, Raúl, et al.
Publicado: (2015)

Clinical Relevance of +936 C>T VEGFA and c.233C>T bFGF Polymorphisms in Chronic Lymphocytic Leukemia
por: Ballester, Sandra, et al.
Publicado: (2020)

MicroRNA profile in very young women with breast cancer
por: Peña-Chilet, Maria, et al.
Publicado: (2014)

Aurora kinases in ovarian cancer
por: Pérez-Fidalgo, J Alejandro, et al.
Publicado: (2020)

The Novel Oral mTORC1/2 Inhibitor TAK-228 Reverses Trastuzumab Resistance in HER2-Positive Breast Cancer Models
por: Sanz-Álvarez, Marta, et al.
Publicado: (2021)

Deficiency in p53 is required for doxorubicin induced transcriptional activation of NF-κB target genes in human breast cancer
por: Dalmases, Alba, et al.
Publicado: (2013)

CIP2A as a Key Regulator for AKT Phosphorylation Has Partial Impact Determining Clinical Outcome in Breast Cancer
por: Luque, Melani, et al.
Publicado: (2022)

Targeted Therapy Modulates the Secretome of Cancer-Associated Fibroblasts to Induce Resistance in HER2-Positive Breast Cancer
por: Luque, Melani, et al.
Publicado: (2021)

Trastuzumab or lapatinib with standard chemotherapy for HER2-positive breast cancer: results from the GEICAM/2006-14 trial
por: Alba, E, et al.
Publicado: (2014)

EZH2-Myc driven glioblastoma elicited by cytomegalovirus infection of human astrocytes
por: El Baba, Ranim, et al.
Publicado: (2023)

The Hippo Pathway Transducers YAP1/TEAD Induce Acquired Resistance to Trastuzumab in HER2-Positive Breast Cancer
por: González-Alonso, Paula, et al.
Publicado: (2020)

Detection of TP53 and PIK3CA Mutations in Circulating Tumor DNA Using Next-Generation Sequencing in the Screening Process for Early Breast Cancer Diagnosis
por: Jimenez Rodriguez, Begona, et al.
Publicado: (2019)

The GATA3 X308_Splice breast cancer mutation is a hormone context-dependent oncogenic driver
por: Hruschka, Natascha, et al.
Publicado: (2020)

EZH1 and EZH2 promote skeletal growth by repressing inhibitors of chondrocyte proliferation and hypertrophy
por: Lui, Julian C., et al.
Publicado: (2016)

Acceleration in the DNA methylation age in breast cancer tumours from very young women
por: Oltra, Sara S., et al.
Publicado: (2019)

Interplay between Natural Killer Cells and Anti-HER2 Antibodies: Perspectives for Breast Cancer Immunotherapy
por: Muntasell, Aura, et al.
Publicado: (2017)

Myc Enforces Overexpression of EZH2 in Early Prostatic Neoplasia via Transcriptional and Post-transcriptional Mechanisms
por: Koh, Cheryl M., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_m6qtvbqjqq01jho5ko0molc1cr